[Paliperidone, risperidone]

Nihon Rinsho. 2013 Apr;71(4):654-9.
[Article in Japanese]

Abstract

Risperidone, a serotonin-dopamine antagonist, is effective in preventing delusions and hallucinations by D2 receptor antagonism and treating negative symptoms by 5-HT2A receptor antagonism. It is less likely to produce extrapyramidal symptoms than conventional antipsychotics, enabling safe drug therapy for schizophrenia. Paliperidone, based on 9OH-risperidone(major metabolite of risperidone), was developed to make the best use of the high therapeutic efficacy of Risperdal and enable continued treatment with lower prevalence of adverse events. Its mechanism of action as an extended-release tablet ensures slow release of the active ingredient, contributing to the lower prevalence of adverse events. With these pharmacological characteristics in mind, the two drugs can serve as safe and effective drug therapy.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Antipsychotic Agents / administration & dosage
  • Antipsychotic Agents / therapeutic use*
  • Humans
  • Isoxazoles / administration & dosage
  • Isoxazoles / therapeutic use*
  • Japan
  • Paliperidone Palmitate
  • Pyrimidines / administration & dosage
  • Pyrimidines / therapeutic use*
  • Receptor, Serotonin, 5-HT2A / metabolism
  • Risperidone / administration & dosage
  • Risperidone / therapeutic use*
  • Schizophrenia / drug therapy*
  • Schizophrenia / metabolism
  • Treatment Outcome

Substances

  • Antipsychotic Agents
  • Isoxazoles
  • Pyrimidines
  • Receptor, Serotonin, 5-HT2A
  • Risperidone
  • Paliperidone Palmitate